Consequently, inhibition of IL-1 by anakinra or canakinumab [50] or of the NLRP3 inflammasome [21] might prevent cancer development or have therapeutic efficacy at the beginning of tumor development, as demonstrated by the CANTOS trial [67,68]. The gene discussed is IL1A; the disease is cancer.